News

A phase 2 study of surufatinib in patients with biliary tract carcinoma showed some benefit and a larger phase 3 study is underway.

In an interview with Targeted Oncology™, Clayton Lau, MD, discussed the impact of COVID-19 on managing genitourinary cancers.

Andrea Holowatyj, PhD, MSCI delved into the growing issue of early-onset appendiceal cancer, how it impacts certain groups, and what efforts can improve outcomes for these patients in the future.

FDA approval is being sought for dovitinib as a treatment option for patients with renal cell carcinoma.

Results from the phase 3 JUPITER-02 trial show that oncologists can extend progression-free survival in patients with nasopharyngeal carcinoma by adding toripalimab to chemotherapy.

Alexandra Higgins,MD, discusses the association of hepatopulmonary syndrome with the long-term use of ado-trastuzumab emtansine.

Annelise Wilhite, MD, a gynecology oncology fellow at the University of South Alabama Health, discusses the difficulty in treating vulvar and vaginal melanomas.

Rana R. McKay, MD, discussed the implications of the KEYNOTE-564 study along with the future of adjuvant immunotherapy in RCC, in an interview with Targeted Oncology

In an interview with Targeted Oncology, Thomas Habermann, MD discusses the current unmet needs in the DLBCL space, along with the future of targeted therapies.

The FDA’s orphan drug designation granted to silmitasertib for medulloblastoma marks the agent’s second such designation.

Ruben Niesvizky, MD, discusses the shift in standard of care treatment for multiple myeloma.

Early research shows that the menin inhibitor, KO-539, may have synergy with other targeted agents for the treatment of KMT2A-rearranged and NPM1-mutated acute myeloid leukemia tumors.

Entospletinib in combination with chemotherapy will be evaluated in the phase 3 AGILITY study in patients with NPM1-mutated AML.

In patients with EGFR-positive non–small cell lung cancer who develop a T790M mutation after disease progression, chemo-antiangiogenesis may prove beneficial.

Findings from the INSEMA study show that patients who received either sentinel lymph node biopsy or complete axillary lymph node dissection experienced differences in breast and arm symptoms compared with patients who did not.

APVO436 appears to be safe and effective for the treatment of acute myeloid leukemia or myelodysplastic syndrome.

E777 is a reformulation of a previous FDA approved agent for CTLC that was pulled from the market voluntarily for improvements.

Tegavivint is being tested in combination with osimertinib in an effort to prolong overall survival and deepen response in EGFR+ NSCLC.

ST101 was granted a fast track designation based on preliminary data of an ongoing phase 1/2 trial.

In a phase 3 clinical trial, avasopasem appeared to lower the rate of severe oral mucositis in patients.

The FDA has granted approval to abatacept, the first drug for the prevention of graft versus host disease.

Following an orphan drug designation earlier in 2021, NUV-422 has been granted a fast track designation for the treatment of high-grade gliomas.

All 248 patients with endometrial cancer have been enrolled in the phase 3 SIENDO clinical trial.

Cilta-Cel produced an overall response of 95% in patients with heavily pretreated multiple myeloma.

Rajneesh Nath, MD, discusses the design of the SIERRA trial (NCT02665065), which evaluated 131 I apamistamab (Iomab-B) in elderly patients with relapsed/refractory acute myeloid leukemia.

Full-dose pacritinib beats ruxolitinib in patients with cytopenic myelofibrosis.

Results from the REVEAL study signal link between thrombotic events and white blood cell counts.

Tisagenlecleucel failed to improve event-free survival in the second-line setting of relapsed or refractory aggreesve B-cell non-Hodgkin lymphoma versus standard-of-care.

The considerations investigators must take into account when designing clinical trials include patient population, previous therapies, assessment of the central nervous system, end points, and leptomeningeal disease, according to the new guidelines.